Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Industry News Roundup

This article was originally published in The Tan Sheet

Executive Summary

DASCA facilitates DEA’s steroid scheduling; U.K. ad authority sneezes at hay fever claim; Nutroganics acquires Wholesoy; hemp migraine relief distribution lit; Clif’s cashew recipe trips some customers; ONHA sponsors GrassrootsHealth nutrient research; baby wipe recall reaches 4M units; and Nasdaq reprieve for Rock Creek.

You may also be interested in...



States’ Proposals To Age-Restrict Sports Nutrition Sales Miss Targeted Problems But Hit Retailers

MA and NY lawmakers propose prohibiting sales to consumers under 18 of supplements, OTC drugs for weight loss and muscle building and imposing $2,000 fines for violations. Supplement industry trade groups say the laws would not help solve eating disorders but would hammer retailers.

US DoJ Has 'Key Focus' On Supplement Industry, Adds 6 Attorneys To Sector

"It is just common sense that there's going to be fraud where you have the combination of high growth, developing science, imported products or ingredients and limited oversight," says David Morrell, deputy assistant US attorney in DoJ'd Consumer Protection Branch. CPB

SARMs Subject To Steroids Scheduling By DEA Under Hatch, Whitehouse Bill

The Utah Republican and Rhode Island Democrat sponsor legislation to make selective androgen receptor modulators subject to the same authority the Drug Enforcement Administration has to regulate anabolic steroids. Hatch said the SARMs Control Act of 2018 would "ensure that the DEA has the authority it needs to prevent abuse and diversion of these dangerous substances.”

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS107346

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel